Success Metrics

Completion Rate
0%(0/1)
Active Trials
4(57%)
Terminated
1(14%)

Phase Distribution

Ph phase_2
5
71%
Ph phase_3
1
14%
Ph phase_1
1
14%

Phase Distribution

1

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
5(71.4%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

4

trials recruiting

Total Trials

7

all time

Status Distribution
Active(4)
Terminated(1)
Other(2)

Detailed Status

Recruiting3
unknown2
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
4
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 25 (71.4%)
Phase 31 (14.3%)

Trials by Status

terminated114%
active_not_recruiting114%
recruiting343%
unknown229%

Recent Activity

4 active trials
Showing 5 of 7
recruitingphase_1

Sapu003 in Advanced mTOR-sensitive Solid Tumors

NCT07369505
active_not_recruitingphase_2

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

NCT05150652
recruitingphase_2

Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.

NCT06364267
recruitingphase_3

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

NCT05512364
terminatedphase_2

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

NCT03874325
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07369505Phase 1

Sapu003 in Advanced mTOR-sensitive Solid Tumors

Recruiting
NCT05150652Phase 2

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

Active Not Recruiting
NCT06364267Phase 2

Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.

Recruiting
NCT05512364Phase 3

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

Recruiting
NCT03874325Phase 2

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Terminated
NCT03024580Phase 2

A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer

Unknown
NCT02646735Phase 2

Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients

Unknown

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7